Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis
Main Article Content
Keywords
Atopic Dermatitis, Biologic, Tralokinumab
Abstract
Abstract not available.
References
2. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.
3. Guttman-Yassky E et al. Semin Cutan Med Surg 2017; 36: 100–103.
4. Czarnowicki T et al. J Allergy Clin Immunol 2019; 143: 1–11.
5. Szegedi K et al. J Eur Acad Dermatol Venereol 2015; 29: 2136–2144.
6. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.
7. Bieber T. Allergy 2020; 75: 54–62.
8. Pavel AB et al. J Am Acad Dermatol 2020; 82: 690–699.
9. Popovic B et al. J Mol Biol 2017; 429: 208–219.
10. Mercieca-Bebber R et al. Patient Relat Outcome Meas 2018; 9: 353–367.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.